Furthermore, this synergistic effect may indeed be demonstrated irrespective of PTPN11′s mutation status and warrants further investigation in PI3K or RAS-driven NSCLC settings, where either PI3K or MAPK targeting is appropriate. This evidence concerns the gene PIK3CA and non-small cell lung carcinoma.